Asymptomatic severe carotid stenosis
- 1 December 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 45 (12) , 2147-2153
- https://doi.org/10.1212/wnl.45.12.2147
Abstract
Objective: To analyze, for patients with asymptomatic severe carotid stenosis, the risks and benefits of two strategies: (1) immediate prophylactic carotid endarterectomy (CEA), and (2) medical management followed by CEA only after a transient ischemic attack (TIA) or a minor stroke has occurred. Design: A Markov-based decision analysis model that simulates and counts the possible clinical outcomes (deaths, TIAs, and major strokes) of the two strategies. Data were drawn from the current literature. Subjects: A hypothetical cohort of asymptomatic patients with severe (more than 75% diameter reduction) carotid stenosis identified by noninvasive diagnostic tests. Main results: Given the immediate surgery-related risks, patients with a stroke incidence without preceding TIA of 3% per year will benefit from prophylactic CEA only if they survive more than 4 years after the procedure, whereas those with a higher stroke incidence (5% per year) will benefit from prophylactic CEA after just 2 years. However, the gain yielded by prophylactic CEA remains small. As age- or cardiovascular-related mortality increases, the maximum tolerated combined surgical mortality and morbidity rate below which prophylactic CEA yields an improved 5-year stroke- and surgery-related-event-free survival decreases--from 5% for patients aged 55 years to 2% for patients aged 85 years with a stroke incidence of 3% per year, and from 8.5% for patients aged 55 years to 4% for patients aged 85 years with a stroke incidence of 5% per year. On the other hand, for risk-intolerant patients who value the 2-year stroke- and surgery-related-event-free survival more than life in the distant future, the combined surgical morbidity and mortality rate below which prophylactic CEA remains the preferred strategy is below 3% at any age. Conclusion: Risk-intolerant patients should not undergo prophylactic CEA. On the other hand, for risk-tolerant patients willing to accept an immediate and dangerous procedure to decrease the future risk of death or chronic disability due to stroke, assessment of both perioperative risk and the risk of premature death from coexistent coronary artery disease should guide individual therapeutic decision-making. NEUROLOGY 1995;45: 2147-2153Keywords
This publication has 12 references indexed in Scilit:
- Differentiation between different pathological cerebral embolic materials using transcranial Doppler in an in vitro model.Stroke, 1993
- Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 studyJournal of the American College of Cardiology, 1992
- Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis.Stroke, 1991
- Presidential address: Who sets the standards?Journal of Vascular Surgery, 1991
- Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and caroteneThe Lancet, 1991
- Presidential address: Who sets the standards?Journal of Vascular Surgery, 1991
- ANTIBODY TITRES TO A ROUGH-MUTANT STRAIN OF ESCHERICHIA COLI IN PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1987
- Cancer induction and non-stochastic effectsThe British Journal of Radiology, 1987
- Detection of Antibodies Directed against a Liver-Specific Membrane Lipoprotein in Patients with Acute and Chronic Active HepatitisNew England Journal of Medicine, 1978